Matches in SemOpenAlex for { <https://semopenalex.org/work/W2264082854> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W2264082854 endingPage "6726" @default.
- W2264082854 startingPage "6726" @default.
- W2264082854 abstract "6726 Background: Acute lymphatic leukemia (ALL) is one of the most curable neoplasia in children, but the results in adults are poor. We evaluated the response, relapse, disease-free survival (DFS) and overall survival (OS) in adults pts with ALL who received treatment with Induction, Intensification, CNS Prophylaxis, Consolidation and Maintenance chemotherapy (9904 Regimen). Induction phase included Cyclophosphamide, Daunomicine, Vincristine, L-asparaginase and Prednisone. Methods: Clinical prospective trial of 9904 Regimen in pts with ALL treated in our institution between 1999–2003. It included pts older than 14y without previous treatment, neither chronic illness of kidney nor liver. We described clinical characteristics of patients; response and relapse rates to treatment. Survival rate was estimated by Kaplan-Meier. Results: We included 231 pts in the present trial. Pts characteristics were: Median age: 18y (14–57) and relationship Male/female: 1.4/1. Extramedullary deposit: 164 (72%) pts. including Lymph nodes involvement:105 (46%) and Hepatosplenomegaly: 49(21%). Median hemoglobin: 7.2gr/L (1.6- 15), median leucocytes count: 12900/L (0.1- 798000) and platelets count: 42000/L (1000- 669000). Signs of DIC in 7%. Characteristics of induction treatment were: Median neutropenia: 30 days, leucocytes nadir: 0.4/L and median number of febrile events: 1 episode (1–11). Toxicity in 105 (45%) pts: including liver toxicity: 79 (35%), hypofibrinogenemia: 75 (33%), hyperamylasemia: 14 (6%).Complete remission (CR) was achieved in 183/231 (79%) pts. Characteristics of failure to induction were: relative resistance to drugs in 50%, death in bone hypoplasia in 19% and persistence of illness at extramedullary deposit in 17% of pts. Until now there are 86/183 pts (47%) with relapses. The median of following was 13.5 months, reaching a 3 year rate DFS of 32% and OS of 55%. Conclusions: This regimen of chemotherapy repeat the results reported in literature for pts with Adult ALL. The induction is effective for reaching CR, but relapses are often. Toxicity was tolerated. No significant financial relationships to disclose." @default.
- W2264082854 created "2016-06-24" @default.
- W2264082854 creator A5001052008 @default.
- W2264082854 creator A5012013959 @default.
- W2264082854 creator A5017769557 @default.
- W2264082854 creator A5020219644 @default.
- W2264082854 creator A5052159944 @default.
- W2264082854 creator A5052889689 @default.
- W2264082854 creator A5072988680 @default.
- W2264082854 creator A5087927604 @default.
- W2264082854 creator A5089404340 @default.
- W2264082854 creator A5089673166 @default.
- W2264082854 date "2005-06-01" @default.
- W2264082854 modified "2023-09-26" @default.
- W2264082854 title "Acute lymphatic leukemia: Peruvian experience" @default.
- W2264082854 doi "https://doi.org/10.1200/jco.2005.23.16_suppl.6726" @default.
- W2264082854 hasPublicationYear "2005" @default.
- W2264082854 type Work @default.
- W2264082854 sameAs 2264082854 @default.
- W2264082854 citedByCount "0" @default.
- W2264082854 crossrefType "journal-article" @default.
- W2264082854 hasAuthorship W2264082854A5001052008 @default.
- W2264082854 hasAuthorship W2264082854A5012013959 @default.
- W2264082854 hasAuthorship W2264082854A5017769557 @default.
- W2264082854 hasAuthorship W2264082854A5020219644 @default.
- W2264082854 hasAuthorship W2264082854A5052159944 @default.
- W2264082854 hasAuthorship W2264082854A5052889689 @default.
- W2264082854 hasAuthorship W2264082854A5072988680 @default.
- W2264082854 hasAuthorship W2264082854A5087927604 @default.
- W2264082854 hasAuthorship W2264082854A5089404340 @default.
- W2264082854 hasAuthorship W2264082854A5089673166 @default.
- W2264082854 hasConcept C126322002 @default.
- W2264082854 hasConcept C141071460 @default.
- W2264082854 hasConcept C2776694085 @default.
- W2264082854 hasConcept C2776755627 @default.
- W2264082854 hasConcept C2777063308 @default.
- W2264082854 hasConcept C2778850193 @default.
- W2264082854 hasConcept C2779429289 @default.
- W2264082854 hasConcept C2781413609 @default.
- W2264082854 hasConcept C71924100 @default.
- W2264082854 hasConcept C90924648 @default.
- W2264082854 hasConceptScore W2264082854C126322002 @default.
- W2264082854 hasConceptScore W2264082854C141071460 @default.
- W2264082854 hasConceptScore W2264082854C2776694085 @default.
- W2264082854 hasConceptScore W2264082854C2776755627 @default.
- W2264082854 hasConceptScore W2264082854C2777063308 @default.
- W2264082854 hasConceptScore W2264082854C2778850193 @default.
- W2264082854 hasConceptScore W2264082854C2779429289 @default.
- W2264082854 hasConceptScore W2264082854C2781413609 @default.
- W2264082854 hasConceptScore W2264082854C71924100 @default.
- W2264082854 hasConceptScore W2264082854C90924648 @default.
- W2264082854 hasIssue "16_suppl" @default.
- W2264082854 hasLocation W22640828541 @default.
- W2264082854 hasOpenAccess W2264082854 @default.
- W2264082854 hasPrimaryLocation W22640828541 @default.
- W2264082854 hasRelatedWork W136411592 @default.
- W2264082854 hasRelatedWork W1499275448 @default.
- W2264082854 hasRelatedWork W1988917052 @default.
- W2264082854 hasRelatedWork W2016341751 @default.
- W2264082854 hasRelatedWork W2042515268 @default.
- W2264082854 hasRelatedWork W2121694206 @default.
- W2264082854 hasRelatedWork W2370952297 @default.
- W2264082854 hasRelatedWork W2385309123 @default.
- W2264082854 hasRelatedWork W2403331838 @default.
- W2264082854 hasRelatedWork W2406181293 @default.
- W2264082854 hasVolume "23" @default.
- W2264082854 isParatext "false" @default.
- W2264082854 isRetracted "false" @default.
- W2264082854 magId "2264082854" @default.
- W2264082854 workType "article" @default.